Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07214818) titled 'SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome' on Oct. 6.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Mansoura University
Condition:
Nephrotic Syndrome
Intervention:
Drug: Dapagliflozin
Drug: Empagliflozin
Recruitment Status: Not recruiting
Phase: Phase 2/Phase 3
Date of First Enrollment: November 15, 2025
Target Sample Size: 75
Countries of Recruitment:
Egypt
To know more, visit https://clinicaltrials.gov/study/NCT07214818
Published by HT Digital Content Servi...